Atossa Therapeutics announced that the U.S. Food and Drug Administration (“FDA”) has granted Rare Pediatric Disease (“RPD”) designation to (Z)-Endoxifen for the treatment of Duchenne Muscular Dystrophy (“DMD”).
“This designation is an important regulatory milestone for Atossa, and we believe a strong validation of the science supporting the potential of (Z)-Endoxifen as a treatment for Duchenne Muscular Dystrophy,” said Steven Quay, M.D., Ph.D., Atossa Therapeutics President and Chief Executive Officer. “DMD is one of the most devastating childhood diseases. Families urgently need better options beyond steroids and gene-targeted approaches. While oncology remains our core focus, this milestone highlights (Z)-Endoxifen’s potential as a platform therapy in both cancer and rare diseases, opening the door to potential non-dilutive value creation through the Rare Pediatric Disease program.”
Table of Contents
What Is Endoxifen?
Endoxifen is an investigational small-molecule therapy and a major active metabolite of tamoxifen, a selective estrogen receptor modulator (SERM) that has been widely used in other indications.
Because endoxifen directly engages estrogen receptors, it has the potential to modulate pathways involved in muscle health, including muscle growth, repair, and fibrosis. Atossa is developing an oral formulation of endoxifen designed to achieve consistent drug exposure and enable convenient, once-daily dosing, subject to ongoing development and evaluation.
Endoxifen is not approved for use in DMD or any muscular dystrophy indication. Its safety and efficacy for these uses have not been established.
Why Endoxifen in DMD?
Skeletal muscle is responsive to hormonal signaling, including estrogen receptor pathways, which can influence:
- Muscle regeneration and repair
- Inflammation and oxidative stress
- Fibrosis and tissue remodeling
Selective estrogen receptor modulators (SERMs) have shown biological activity in muscle and are being explored in various neuromuscular contexts. As a potent, active metabolite, endoxifen may offer:
- Direct estrogen receptor modulation in muscle tissue
- Oral dosing potential, supporting chronic administration if ultimately proven safe and effective
- A mutation-independent mechanism, meaning it could, in principle, be studied across the broader DMD population, regardless of the underlying dystrophin gene mutation
Atossa’s program is designed to rigorously evaluate this scientific rationale through preclinical and, if appropriate, future clinical studies.
Unmet Need and Treatment Landscape
Current DMD management typically involves:
- Corticosteroids, which can help slow disease progression but are associated with significant side effects
- Mutation-specific therapies, such as exon-skipping or gene-targeted approaches, which are available only to patients with certain genetic variants
- Supportive care, including cardiac and respiratory management, physical therapy, and orthopedics
There is a clear need for additional, generally applicable treatment options that could be used alone or alongside existing therapies. A mutation-agnostic, orally administered therapy—if shown to be safe and effective—could potentially reach a broad range of individuals with DMD.
Follow This Page >>> All Clinical Trials for Duchenne
